BR112014010729A2 - métodos para tratamento de ataques de gota - Google Patents
métodos para tratamento de ataques de gotaInfo
- Publication number
- BR112014010729A2 BR112014010729A2 BR112014010729A BR112014010729A BR112014010729A2 BR 112014010729 A2 BR112014010729 A2 BR 112014010729A2 BR 112014010729 A BR112014010729 A BR 112014010729A BR 112014010729 A BR112014010729 A BR 112014010729A BR 112014010729 A2 BR112014010729 A2 BR 112014010729A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- gout attacks
- treating gout
- urate
- attacks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/059433 WO2013066353A1 (en) | 2011-11-04 | 2011-11-04 | Methods for treating gout flares |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014010729A2 true BR112014010729A2 (pt) | 2018-03-20 |
Family
ID=48192537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014010729A BR112014010729A2 (pt) | 2011-11-04 | 2011-11-04 | métodos para tratamento de ataques de gota |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2775836B8 (enExample) |
| JP (1) | JP6008974B2 (enExample) |
| KR (1) | KR101848121B1 (enExample) |
| CN (2) | CN104066324A (enExample) |
| AU (1) | AU2011380510B2 (enExample) |
| BR (1) | BR112014010729A2 (enExample) |
| CA (1) | CA2859693C (enExample) |
| CL (1) | CL2014001157A1 (enExample) |
| DK (1) | DK2775836T3 (enExample) |
| EA (1) | EA201490928A1 (enExample) |
| ES (1) | ES2698396T3 (enExample) |
| IL (1) | IL232384A (enExample) |
| MX (1) | MX357510B (enExample) |
| NZ (1) | NZ624726A (enExample) |
| PH (1) | PH12014500990A1 (enExample) |
| PL (1) | PL2775836T3 (enExample) |
| SG (1) | SG11201401981TA (enExample) |
| WO (1) | WO2013066353A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2538357T3 (es) | 2005-04-11 | 2015-06-19 | Crealta Pharmaceuticals Llc | Formas variantes de urato oxidasa y uso de las mismas |
| US9377454B2 (en) | 2009-06-25 | 2016-06-28 | Crealta Pharmaceuticals Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| US8918181B2 (en) | 2010-11-16 | 2014-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treatment of dry eye |
| EP2836209A4 (en) * | 2012-04-13 | 2015-11-25 | Cymabay Therapeutics Inc | METHOD FOR THE TREATMENT OF HYPERURICEMIA IN PATIENTS WITH A GOG THROUGH HALOFENATE OR HALOFENIC ACID AND AN INFLAMMATORY INHIBITOR |
| JP2019535819A (ja) * | 2016-11-11 | 2019-12-12 | ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーＨｏｒｉｚｏｎ Ｐｈａｒｍａ Ｒｈｅｕｍａｔｏｌｏｇｙ Ｌｌｃ | プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用 |
| WO2019082335A1 (ja) * | 2017-10-26 | 2019-05-02 | 大塚製薬株式会社 | イノシトールリン酸含有組成物 |
| CN109223707B (zh) * | 2018-09-13 | 2020-12-08 | 中国药科大学 | 一种尿酸酶外用凝胶制剂、其制备方法及用途 |
| WO2020160325A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| CN114028584B (zh) * | 2021-11-18 | 2023-09-05 | 辽宁万嘉医药科技有限公司 | 一种降尿酸的多酚多元环糊精包合物及其制备方法 |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
| KR20250085216A (ko) | 2023-12-05 | 2025-06-12 | 인제대학교 산학협력단 | 알코올 스프레이를 활용한 환자 냉각장치 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| US6624194B1 (en) | 1999-06-04 | 2003-09-23 | Metabolex, Inc. | Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| EP1865954A4 (en) * | 2005-03-21 | 2010-12-15 | Metabolex Inc | METHOD FOR AVOIDING OEDEM IN THE TREATMENT OR PREVENTION OF DISEASES AFFECTING PPAR GAMMA INCLUDING CANCER |
| CN103058944B (zh) * | 2007-11-27 | 2015-08-05 | 亚德生化公司 | 调节血液尿酸水平的化合物 |
| ES2561039T3 (es) * | 2008-04-30 | 2016-02-24 | Wellstat Therapeutics Corporation | Compuestos tetrazol para reducir el ácido úrico |
-
2011
- 2011-11-04 SG SG11201401981TA patent/SG11201401981TA/en unknown
- 2011-11-04 KR KR1020147015186A patent/KR101848121B1/ko not_active Expired - Fee Related
- 2011-11-04 EP EP11875217.9A patent/EP2775836B8/en not_active Not-in-force
- 2011-11-04 EA EA201490928A patent/EA201490928A1/ru unknown
- 2011-11-04 NZ NZ624726A patent/NZ624726A/en not_active IP Right Cessation
- 2011-11-04 CN CN201180076190.XA patent/CN104066324A/zh active Pending
- 2011-11-04 CA CA2859693A patent/CA2859693C/en not_active Expired - Fee Related
- 2011-11-04 PL PL11875217T patent/PL2775836T3/pl unknown
- 2011-11-04 AU AU2011380510A patent/AU2011380510B2/en not_active Ceased
- 2011-11-04 JP JP2014541013A patent/JP6008974B2/ja not_active Expired - Fee Related
- 2011-11-04 ES ES11875217T patent/ES2698396T3/es active Active
- 2011-11-04 BR BR112014010729A patent/BR112014010729A2/pt not_active Application Discontinuation
- 2011-11-04 WO PCT/US2011/059433 patent/WO2013066353A1/en not_active Ceased
- 2011-11-04 CN CN201810759998.1A patent/CN109045009A/zh active Pending
- 2011-11-04 DK DK11875217.9T patent/DK2775836T3/en active
- 2011-11-04 MX MX2014005398A patent/MX357510B/es active IP Right Grant
-
2014
- 2014-04-30 IL IL232384A patent/IL232384A/en active IP Right Grant
- 2014-05-02 PH PH12014500990A patent/PH12014500990A1/en unknown
- 2014-05-02 CL CL2014001157A patent/CL2014001157A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011380510A1 (en) | 2014-05-29 |
| KR20140121384A (ko) | 2014-10-15 |
| CL2014001157A1 (es) | 2015-01-16 |
| MX2014005398A (es) | 2015-04-08 |
| EA201490928A1 (ru) | 2014-11-28 |
| IL232384A0 (en) | 2014-06-30 |
| SG11201401981TA (en) | 2014-05-29 |
| EP2775836A4 (en) | 2015-05-20 |
| NZ624726A (en) | 2016-01-29 |
| JP6008974B2 (ja) | 2016-10-19 |
| ES2698396T3 (es) | 2019-02-04 |
| AU2011380510B2 (en) | 2016-05-12 |
| EP2775836B1 (en) | 2018-09-12 |
| EP2775836B8 (en) | 2018-10-24 |
| CN104066324A (zh) | 2014-09-24 |
| DK2775836T3 (en) | 2018-12-03 |
| MX357510B (es) | 2018-07-12 |
| CA2859693A1 (en) | 2013-05-10 |
| CN109045009A (zh) | 2018-12-21 |
| JP2014532760A (ja) | 2014-12-08 |
| EP2775836A1 (en) | 2014-09-17 |
| IL232384A (en) | 2017-10-31 |
| PL2775836T3 (pl) | 2019-02-28 |
| KR101848121B1 (ko) | 2018-04-11 |
| WO2013066353A1 (en) | 2013-05-10 |
| CA2859693C (en) | 2018-05-22 |
| PH12014500990A1 (en) | 2014-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014010729A2 (pt) | métodos para tratamento de ataques de gota | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| EA201490396A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| EA028156B9 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
| BR112013031032A2 (pt) | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos | |
| MX338916B (es) | Oxazepinas como moduladores del canal de iones. | |
| BR112014000240A2 (pt) | derivados de benzilamina como inibidores de calicreína plasmática | |
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| WO2015031564A3 (en) | Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| EA201300669A1 (ru) | Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| BR112014032699A2 (pt) | métodos de tratamento de síndrome metabólica pediátrica | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| EA201290859A1 (ru) | Лечение люпус-артрита с использованием лаквинимода | |
| BR112014004435A2 (pt) | inibidores de quinase rock | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| BR112012027080A2 (pt) | composições orgânicas para tratar doenças relacionadas a beta - ena | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| EA201490045A1 (ru) | Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
| BR112014002915A2 (pt) | inibidores de pde4 suaves | |
| CA2787512C (en) | A method of treating sinusitis, including chronic sinusitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 37/00 , A61K 31/20 Ipc: A61K 31/047 (2006.01), A61K 31/09 (2006.01), A61K |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |